Elite Pharma Inc (ELTP) 0.3660 $ELTP
Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating
Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide the year end business update at 12:00 PM ET on Tuesday, July 1, 2014. Company executives will conduct a question and answer session following their remarks.
Elite Pharmaceuticals signs USD5m settlement agreement with Novel Laboratories and other related parties
M2 - Wed Jun 11, 7:22AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) announced on Tuesday a USD5m settlement agreement with Novel Laboratories, Veerappan S. Subramanian, VGS Pharma and other related parties (the VGS parties).
Elite Pharmaceuticals Enters Into $5 Million Settlement Agreement With Novel Laboratories
GlobeNewswire - Tue Jun 10, 10:11AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) entered into a settlement agreement with Novel Laboratories, Inc. ("Novel" , Veerappan S. Subramanian ("Subramanian" , VGS Pharma, LLC ("VGS" and other related parties (all of the foregoing collectively, the "VGS Parties" pursuant to which the 2006 Strategic Alliance Agreement and Stockholders Agreement with Subramanian and VGS (collectively, the "Agreement" were terminated and all parties executed mutual releases. In addition, the VGS Parties paid Elite $5,000,000 in exchange for 9,800 shares of Novel Class A common stock owned by Elite. This resolves all disputes and claims between Elite and the VGS Parties, including those alleged in the action commenced by Elite against the VGS Parties on April 28, 2014, and ends Elite's ownership in Novel.
Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
GlobeNewswire - Mon Jun 09, 7:01AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human abuse liability clinical study for ELI-200. ELI-200 is an abuse deterrent product for an undisclosed opioid. The study is a randomized, double-blind, double-dummy, active and placebo-controlled five-way crossover study comparing crushed ELI-200 capsules to a comparator product. The primary objective of the study is to assess the abuse potential when administered intranasally of ground ELI-200 relative to a crushed comparator product and the secondary objectives include determining relative bioavailability and safety of the product. Completion of the dosing is expected in approximately 2 months. Final study results are expected later this year.
Adherex Technologies Sees Share Volume Shoot Through The Roof
ACCESSWIRE - Tue May 27, 3:18PM CDT
Adherex Technologies Inc. (OTCQB: ADHXF) saw its share volume skyrocket on May 27th with 627,393 shares exchanging hands, twelve times higher than its three month daily average volume of 50,914 shares.
Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
GlobeNewswire - Fri May 23, 10:08AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) today announced the voting results of matters considered during the Company's annual meeting of shareholders held on May 21, 2014. Of the shares entitled to vote at this meeting, 89.18% shares were voted for this meeting.
ChromaDex Announces Second Human Clinical Trial
ACCESSWIRE - Wed May 21, 8:28AM CDT
ChromaDex Inc. (OTCQB: CDXC) saw its share volume soar on May 20th with 224,975 shares exchanging hands, significantly higher than its three month daily average volume of 143,835 shares.
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
GlobeNewswire - Mon May 19, 7:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-202, an undisclosed opioid abuse deterrent product, utilizing Elite's proprietary pharmacological abuse deterrent technology.
Provectus Biopharmaceutical's Share Volume Skids
ACCESSWIRE - Mon May 12, 10:13AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) saw its share volume slide on May 9th with 283,582 shares exchanging hands, significantly lower than its three month daily average of 696,514 shares.
Elite Pharmaceuticals Showing Long Term Promise, Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon May 05, 6:30AM CDT
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) develops oral sustained and controlled release products. Elite has eight commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology.
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.
OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.
Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.
Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY
Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.
Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating
Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide the year end business update at 12:00 PM ET on Tuesday, July 1, 2014. Company executives will conduct a question and answer session following their remarks. Elite Pharmaceuticals signs USD5m settlement agreement with Novel Laboratories and other related parties
M2 - Wed Jun 11, 7:22AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) announced on Tuesday a USD5m settlement agreement with Novel Laboratories, Veerappan S. Subramanian, VGS Pharma and other related parties (the VGS parties).
Elite Pharmaceuticals Enters Into $5 Million Settlement Agreement With Novel Laboratories
GlobeNewswire - Tue Jun 10, 10:11AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) entered into a settlement agreement with Novel Laboratories, Inc. ("Novel" , Veerappan S. Subramanian ("Subramanian" , VGS Pharma, LLC ("VGS" and other related parties (all of the foregoing collectively, the "VGS Parties" pursuant to which the 2006 Strategic Alliance Agreement and Stockholders Agreement with Subramanian and VGS (collectively, the "Agreement" were terminated and all parties executed mutual releases. In addition, the VGS Parties paid Elite $5,000,000 in exchange for 9,800 shares of Novel Class A common stock owned by Elite. This resolves all disputes and claims between Elite and the VGS Parties, including those alleged in the action commenced by Elite against the VGS Parties on April 28, 2014, and ends Elite's ownership in Novel. Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
GlobeNewswire - Mon Jun 09, 7:01AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human abuse liability clinical study for ELI-200. ELI-200 is an abuse deterrent product for an undisclosed opioid. The study is a randomized, double-blind, double-dummy, active and placebo-controlled five-way crossover study comparing crushed ELI-200 capsules to a comparator product. The primary objective of the study is to assess the abuse potential when administered intranasally of ground ELI-200 relative to a crushed comparator product and the secondary objectives include determining relative bioavailability and safety of the product. Completion of the dosing is expected in approximately 2 months. Final study results are expected later this year. Adherex Technologies Sees Share Volume Shoot Through The Roof
ACCESSWIRE - Tue May 27, 3:18PM CDT
Adherex Technologies Inc. (OTCQB: ADHXF) saw its share volume skyrocket on May 27th with 627,393 shares exchanging hands, twelve times higher than its three month daily average volume of 50,914 shares.
Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
GlobeNewswire - Fri May 23, 10:08AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
("Elite" (OTCBB:ELTP) today announced the voting results of matters considered during the Company's annual meeting of shareholders held on May 21, 2014. Of the shares entitled to vote at this meeting, 89.18% shares were voted for this meeting. ChromaDex Announces Second Human Clinical Trial
ACCESSWIRE - Wed May 21, 8:28AM CDT
ChromaDex Inc. (OTCQB: CDXC) saw its share volume soar on May 20th with 224,975 shares exchanging hands, significantly higher than its three month daily average volume of 143,835 shares.
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
GlobeNewswire - Mon May 19, 7:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
("Elite" (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-202, an undisclosed opioid abuse deterrent product, utilizing Elite's proprietary pharmacological abuse deterrent technology. Provectus Biopharmaceutical's Share Volume Skids
ACCESSWIRE - Mon May 12, 10:13AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) saw its share volume slide on May 9th with 283,582 shares exchanging hands, significantly lower than its three month daily average of 696,514 shares.
Elite Pharmaceuticals Showing Long Term Promise, Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon May 05, 6:30AM CDT
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) develops oral sustained and controlled release products. Elite has eight commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology.
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer. OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.
Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility. Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY
Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe. Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions. 
